Evidence map›Paper›PMID 41739756›Full record

ArticlePloS one2026

Sex, age, and racial/ethnic disparities in hyperuricemia prevalence and risk factors among U.S. adults: An analysis of NHANES 2007-2018 data.

Yadan Zou, Lina Zhang, Jing Xu, Ji Li, Jing Zhang, Ting Long, Ruohan Yu, Yanfeng Zhang, Zhongxing Zhao, Sheng-Guang Li

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yadan ZouDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Lina ZhangDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Jing XuDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Ji LiDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Jing ZhangDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Ting LongDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Ruohan YuDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Yanfeng ZhangDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Zhongxing ZhaoShenyang Medical College, ShenYang, Liao Ning, China.
Sheng-Guang LiDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.ORCID https://orcid.org/0000-0002-8047-9984

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperuricemia is a metabolic disorder linked to gout, kidney disease, and cardiovascular complications. Understanding its prevalence and risk factors across demographic groups is crucial for effective prevention and management.

objectivesTo evaluate the prevalence of hyperuricemia among U.S. adults by sex, age, and racial/ethnic groups, and identify common and sex-specific risk factors.

methodsData from 34,144 U.S. adults aged ≥20 years, obtained from the National Health and Nutrition Examination Survey (NHANES) 2007-2018, were analyzed. Hyperuricemia was defined as serum uric acid levels >7.0 mg/dL in males and >6.0 mg/dL in females. Prevalence estimates were calculated, and multivariate logistic regression models identified risk factors, adjusting for confounders such as body mass index (BMI), alcohol consumption, hypertension, renal function, and other variables. A sensitivity analysis excluding participants with a history of gout was conducted to evaluate the robustness of identified associations.

resultsThe overall prevalence of hyperuricemia was significantly higher in males (21.1%) compared to females (17.1%, P < 0.001). Females surpassed males in both prevalence and absolute numbers after age 50-59; by age ≥ 80, the number of female cases was more than twice that of males. Non-Hispanic Black adults had the highest prevalence (23.9% in males, 23.4% in females). Key risk factors for both sexes included obesity (OR = 3.91 in males; OR = 4.76 in females), hypertension (OR = 1.65 in males; OR = 2.09 in females), and impaired renal function (eGFR < 30 mL/min/1.73 m²: OR = 3.72 in males; OR = 15.37 in females). Alcohol consumption was positively associated with hyperuricemia in males (OR = 1.25), but not significantly so in females. Diabetes showed opposite associations: protective in males (OR = 0.72) but a risk factor in females (OR = 1.22). Medication use exhibited expected directional effects: diuretic use was associated with significantly increased risk of hyperuricemia (OR = 2.67 in males; OR = 2.55 in females), while urate-lowering therapy was associated with reduced risk (OR = 0.57 in males; OR = 0.55 in females).

conclusionsHyperuricemia remains highly prevalent in the U.S., with notable disparities by sex, age, and race/ethnicity. Older women bear a particularly high burden, partly due to obesity, renal dysfunction, and diuretic use. Incorporating medication use into analyses strengthens the evidence for sex-specific risk profiles. These findings highlight the importance of considering targeted screening and prevention strategies in specific high-risk groups, such as older women and patients receiving diuretics.

Indexed as

Health InequitiesHyperuricemiaAdultAgedAge FactorsEthnicityFemaleHumansMaleMiddle AgedNutrition SurveysPrevalenceRacial GroupsRisk FactorsSex FactorsUnited States

Identifiers

PMID41739756
PMCPMC12935233

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.